Role of platelets in restenosis after percutaneous coronary revascularization

Journal of the American College of Cardiology

Volumn 28, Issue 7, 1996, Pages 1643-1651

  Le Breton, Herve ^a   Plow, Edward F ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRONECTIN; GLYCOPROTEIN ANTAGONIST; INTEGRIN; LAMIFIBAN; MEMBRANE RECEPTOR; MONOCLONAL ANTIBODY; PEPTIDE; TIROFIBAN; UNCLASSIFIED DRUG; XEMILOFIBAN;

CLINICAL TRIAL; CORONARY ARTERY DILATATION; CORONARY ARTERY OBSTRUCTION; HUMAN; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; REVIEW; THROMBOCYTE; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0030478359     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(96)00417-2     Document Type: Article

References (107)

1. Gruentzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-8.
2. David PR, Waters DD, Scholl JM, et al. Percutaneous transluminal coronary angioplasty in patients with variant angina. Circulation 1982;66: 695-702.
3. Essed CE, Van den Brand M, Becker AE. Transluminal coronary angioplasty and early restenosis. Fibrocellular occlusion after wall laceration. Br Heart J 1983;49:393-6.
4. Meyer J, Schmitz HJ, Kiesslicht T, et al. Percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris: analysis of early and late results. Am Heart J 1983;106:973-80.
5. Hillegass WB, Ohman EM, Califf RM. Restenosis: clinical issues. In: Topol EJ, editor. Textbook of Interventional Cardiology. Philadelphia: W.B. Saunders, 1994:415-35.
6. Franklin SM, Faxon DP. Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials. Coron Artery Dis 1993;4:232-42.
7. Topol EJ, Califf RM, Weisman HF, et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
8. Ruggeri ZM. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol 1994;31:229-39.
9. Casscells W. Migration of smooth muscle and endothelial cells. Critical events in restenosis. Circulation 1992;86:723-9.
10. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991;253:1129-32.
11. Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 1991;68:106-13.
12. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 1991;88:3739-43.
13. Unterberg C, Meyer T, Smolenski A, Buchwald AB. Platelet-stimulated proliferation of coronary smooth muscle cells [abstract]. J Am Coll Cardiol 1995;25:71A.
14. Shimokawa H, Ito A, Fukumoto Y, et al. Chronic treatment with interleukin-1b induces coronary intimal lesions and vasospastic responses in pigs in vivo. J Clin Invest 1996;97:769-76.
15. Steele PM, Chesebro JH, Stanson AW, et al. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. Circ Res 1985;57:105-12.
16. Wilentz JR, Sanborn TA, Haudenschild CC, Valeri CR, Ryan TJ, Faxon DP. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation 1987;75:636-42.
17. Fingerle J, Johnson R, Clowes AW, Majesky MW, Reidy MA. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci USA 1989;86:8412-6.
18. Lam JY, Chesebro JH, Steele PM, Dewanjee MK, Badimon L, Fuster V. Deep arterial injury during experimental angioplasty: relation to a positive indium-111-labeled platelet scintigram, quantitative platelet deposition and mural thrombosis. J Am Coll Cardiol 1986;8:1380-6.
19. Lam JY, Chesebro JH, Steele PM, et al. Antithrombotic therapy for deep arterial injury by angioplasty. Efficacy of common platelet inhibition compared with thrombin inhibition in pigs. Circulation 1991;84:814-20.
20. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988;77:1213-20.
21. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986;78:1456-61.
22. Ikeda Y, Handa M, Kawano K, et al. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991;87:1234-40.
23. Moake JL, Turner NA, Stathopoulos NA, Nolasco L, Hellums JD. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 1988;71: 1366-74.
24. Moritz MW, Reimers RC, Baker RK, Sutera SP, Joist JH. Role of cytoplasmic and releasable ADP in platelet aggregation induced by laminar shear stress. J Lab Clin Med 1983;101:537-44.
25. Siegel JM, Markou CP, Ku DN, Hanson SR. A scaling law for wall shear rate through an arterial stenosis. J Biomech Eng 1994;116:446-51.
26. Barstad RM, Roald HE, Cui Y, Turitto VT, Sakariassen KS. A perfusion chamber developed to investigate thrombus formation and shear profiles in flowing native human blood at the apex of well-defined stenosis. Arterioscl Thromb Vasc Biol 1994;14:1984-91.
27. Friedman RJ, Stemerman MB, Wenz B, et al. The effect of thrombocytopenia on experimental arteriosclerotic lesion formation in rabbits. Smooth muscle cell proliferation and re-endothelialization. J Clin Invest 1977;60: 1191-201.
28. Faxon DP, Balelli LA, Sandborn T, Haudenschild C, Valeri R, Ryan TJ. The effect of antiplatelet therapy on platelet accumulation after experimental angioplasty in the rabbit iliac model. Int J Cardiol 1992;36:41-7.
29. Faxon DP, Sanborn TA, Haudenschild CC, Ryan TJ. Effect of antiplatelet therapy on restenosis after experimental angioplasty. Am J Cardiol 1984; 53:72C-76C.
30. Radic ZS, O'Malley MK, Mikat EM, et al. The role of aspirin and dipyridamole on vascular DNA synthesis and intimal hyperplasia following deendothelialization. J Surg Res 1986;41:84-91.
31. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-9.
32. Mak KH, Topol EJ. Clinical trials to prevent restenosis after percutaneous coronary revascularization. Ann N Y Acad Sci 1996. In press.
33. White CW, Knudson M, Schmidt D, et al., for the Ticlopidine Study Group. Neither ticlopidine nor aspirin-dipyridamole prevents restenosis post-PTCA: results from a randomized, placebo-controlled multicenter trial [abstract]. Circulation 1987;76 Suppl IV:IV-213A.
34. Bertrand ME, Allain H, Lablanche JM. Results of a randomized trial of ticlopidine versus placebo for prevention of acute closure and restenosis after coronary angioplasty. The TACT study [abstract]. Circulation 1990;82 Suppl III:III-190A.
35. 2-Antagonism Study (CARPORT). Circulation 1991;84:1568-80.
36. Savage MP, Goldberg S, Macdonald RG, et al. Multi-Hospital Eastern Atlantic Restenosis Trial. II. A placebo-controlled trial of thromboxane blockade in the prevention of restenosis following coronary angioplasty. Am Heart J 1991;122:1239-44.
37. 2 blockade on clinical outcome and restenosis after successful coronary angioplasty: Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). Circulation 1995;92:3194-200.
38. Chronos NAF, Wilson DJ, Janes SL, Hutton RA, Buller NP, Goodall AH. Aspirin does not affect the flow cytometric detection of fibrinogen binding to, or release of alpha-granules or lysosomes from, human platelets. Clin Sci 1994;87:575-80.
39. Nurden AT, Nurden P. A review of the role of platelet membrane glycoproteins in the platelet-vessel wall interaction. Baillieres Clin Haematol 1993;6:653-90.
40. Nurden P, Heilmann E, Paponneau A, Nurden A. Two-way trafficking of membrane glycoproteins on thrombin-activated human platelets. Semin Hematol 1994;31:240-50.
41. Ginsberg MH, Xiaoping D, O'Toole TE, Loftus JC, Plow EF. Platelet integrins. Thromb Haemost 1993;70:87-93.
42. Calvete JJ. Clues for understanding the structure and function of a prototypic human integrin: the platelet glycoprotein IIb/IIIa complex. Thromb Haemost 1994;72:1-15.
43. Lopez JA. The platelet glycoprotein Ib-IX complex. Blood Coagul Fibrinolysis 1994;5:97-119.
44. Nurden AT, Caen JP. Specific roles for platelet surface glycoproteins in platelet function. Nature 1975;255:720-2.
45. Berndt MC, Gregory C, Kabral A, Zola H, Fournier D, Castaldi PA. Purification and preliminary characterization of the glycoprotein Ib complex in the human platelet membrane. Eur J Biochem 1985;151:637-49.
46. Du X, Beutler L, Ruan C, Castaldi PA, Berndt MC. Glycoprotein Ib and glycoprotein IX are fully complexed in the intact platelet membrane. Blood 1987;69:1524-7.
47. Chow TW, Hellums JD, Moake JL, Kroll MH. Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. Blood 1992;80:113-20.
48. Roth GJ. Developing relationships: arterial platelet adhesion, glycoprotein Ib, and leucine-rich glycoproteins. Blood 1991;77:5-19.
49. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
50. Cox D, Aoki T, Seki J, Motoyama Y, Yoshida K. The pharmacology of the integrins. Med Res Rev 1994;14:195-228.
51. Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J 1990;4:2868-80.
52. Ginsberg MH, Loftus JC, Plow EF. Cytoadhesins, integrins, and platelets. Thromb Haemost 1988;59:1-6.
53. Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie GA, Ginsberg MH. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci USA 1985;82: 8057-61.
54. Kloczewiak M, Timmons S, Bednarek MA, Sakon M, Hawiger J. Platelet receptor recognition domain on the gamma chain of human fibrinogen and its synthetic peptide analogues. Biochemistry 1989;28:2915-9. Erratum in: Biochemistry 1989;28:7974.
55. Plow EF, D'Souza SE, Ginsberg MH. Ligand binding to GPIIb-IIIa: a status report. Semin Thromb Hemost 1992;18:324-32.
56. Coller BS, Cheresh DA, Asch E, Seligsohn U. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood 1991;77:75-83.
57. Lam SC, Plow EF, D'Souza SE, Cheresh DA, Frelinger AD, Ginsberg MH. Isolation and characterization of a platelet membrane protein related to the vitronectin receptor. J Biol Chem 1989;264:3742-9.
58. Fitzgerald LA, Poncz M, Steiner B, Rail SJ, Bennett JS, Phillips DR. Comparison of cDNA-derived protein sequences of the human fibronectin and vitronectin receptor alpha-subunits and platelet glycoprotein IIb. Biochemistry 1987;26:8158-65.
59. Buchanan MR, Bertomeu MC, Haas TA, Orr FW, Eltringham SL. Localization of 13-hydroxyoctadecadienoic acid and the vitronectin receptor in human endothelial cells and endothelial cell/platelet interactions in vitro. Blood 1993;81:3303-12.
60. Brown SL, Lundgren CH, Nordt T, Fuji S. Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis. Cardiovasc Res 1994;28:1815-20.
61. Murphy JF, Bordet JC, Wyler B, et al. The vitronectin receptor (alpha v beta 3) is implicated, in cooperation with P-selectin and platelet-activating factor, in the adhesion of monocytes to activated endothelial cells. Biochem J 1994;304:537-42.
62. Lafrenie RM, Podor TJ, Buchanan MR, Orr FW. Up-regulated biosynthesis and expression of endothelial cell vitronectin receptor enhances cancer cell adhesion. Cancer Res 1992;52:2202-8.
63. Shaughnessy SG, Lafrenie RM, Buchanan MR, Podor TJ, Orr FW. Endothelial cell damage by Walker carcinosarcoma cells is dependent on vitronectin receptor-mediated tumor cell adhesion. Am J Pathol 1991;138: 1535-43.
64. Clyman RI, Mauray F, Kramer RH. Beta 1 and beta 3 integrins have different roles in the adhesion and migration of vascular smooth muscle cells on extracellular matrix. Exp Cell Res 1992;200:272-84.
65. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res 1994;74:214-24.
66. Yue TL, McKenna PJ, Ohlstein EH, et al. Osteopontin-stimulated vascular smooth muscle cell migration is mediated by beta 3 integrin. Exp Cell Res 1994;214:459-64.
67. Liaw L, Lindner V, Schwartz SM, Chambers AF, Giachelli CM. Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp dependent endothelial migration in vitro. Circ Res 1995;77:665-72.
68. Shattil SJ. Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Thromb Haemost 1995;74:149-55.
69. D'Souza SE, Byers-Ward V, Plow EF. Fibrinogen bridges platelets to endothelial cells [abstract]. FASEB J 1994;8:A267.
70. Topol EJ, Plow EF. Clinical trials of platelet receptor inhibitors. Thromb Haemost 1993;70:94-8.
71. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
72. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985;76:101-8.
73. Turner NA, Moake JL, Kamat SG, et al. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. Circulation 1995;91:1354-62.
74. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-64.
75. Konstantopoulos K, Kamat SG, Schafer AI, et al. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation 1995;91:1427-31.
76. Nicolini FA, Lee P, Rios G, Kottke MK, Topol EJ. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 1994;89:1802-9.
77. Uthoff K, Zehr KJ, Geerling R, Herskowitz A, Cameron DE, Reitz BA. Inhibition of platelet adhesion during cardiopulmonary bypass reduces postoperative bleeding. Circulation 1994;90:11269-74.
78. Tcheng JE, Harrington RA, Kottke MK, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation 1995;91:2151-7.
79. Collen D, Lu HR, Stassen JM, et al. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemost 1994;71:95-102.
80. Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 1994;90:2203-6.
81. Mazur C, Tschopp JF, Faliakou EC, et al. Selective alpha IIb beta 3 receptor blockage with peptide TP9201 prevents platelet uptake on Dacron vascular grafts without significant effect on bleeding time. J Lab Clin Med 1994;124:589-99.
82. Yuan AS, Hand EL, Hichens M, et al. Determination of MK-852, a new fibrinogen receptor antagonist, in plasma and urine by radioimmunoassay. J Pharm Biomed Anal 1993;11:427-34.
83. Vickers S, Duncan CA, Yuan AS, Vyas KP. Disposition of MK-852, a fibrinogen receptor antagonist, in rats and dogs. Drug Metab Dispos 1994;22:631-6.
84. Nichols AJ, Vasko JA, Valocik RE, et al. The in vitro pharmacological profile of SK&F 106760, a novel GPIIB/IIIA antagonist. Thromb Res 1994;75:143-56.
85. Nichols AJ, Vasko JA, Koster PF, et al. The in vivo pharmacological profile of the novel glycoprotein IIb/IIIa antagonist, SK&F 106760. J Pharmacol Exp Ther 1994;270:614-21.
86. Willette RN, Sauermelch CF, Rycyna R, et al. Antithrombotic effects of a platelet fibrinogen receptor antagonist in a canine model of carotid artery thrombosis. Stroke 1992;23:703-11.
87. Mousa SA, Bozarth JM, Forsythe MS, et al. Antiplatelet efficacy and specificity of DMP728, a novel platelet GPIIb/IIIa receptor antagonist. Cardiology 1993;83:374-82.
88. Mousa SA, Bozarth JM, Forsythe MS, et al. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation 1994;89:3-12.
89. Mousa SA, Flint S, Lorelli W, et al. Intravenous antiplatelet efficacy and safety of the platelet GPIIb/IIIa antagonist, DMP 728 in anesthetized dogs. Thromb Res 1994;76:109-19.
90. Rote WE, Davis JH, Mousa SA, Reilly TM, Lucchesi BR. Antithrombotic effects of DMP 728, a platelet GPIIb/IIIa receptor antagonist, in a canine model of arterial thrombosis. J Cardiovasc Pharmacol 1994;23:681-9.
91. Roux S, Carteaux JP, Hess P, Falivene L, Clozel JP. Experimental carotid thrombosis in the guinea pig. Thromb Haemost 1994;71:252-6.
92. Alig L, Edenhofer A, Hadvary P, et al. Low molecular weight, non-peptide fibrinogen receptor antagonists. J Med Chem 1992;35:4393-407.
93. Egbertson MS, Chang CT, Duggan ME, et al. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J Med Chem 1994;37:2537-51.
94. Barrett JS, Murphy G, Peerlinck K, et al. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/ IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther 1994;56:377-88.
95. Cook NS, Zerwes HG, Tapparelli C, et al. Platelet aggregation and fibrinogen binding in human, rhesus monkey, guinea-pig, hamster and rat blood: activation by ADP and a thrombin receptor peptide and inhibition by glycoprotein IIb/IIIa antagonists. Thromb Haemost 1993;70:531-9.
96. Cook NS, Bruttger O, Pally C, Hagenbach A. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active. Thromb Haemost 1993;70:838-47.
97. Nicholson NS, Panzer KS, Salyers AK, et al. SC-54684A: an orally active inhibitor of platelet aggregation. Circulation 1995;91:403-10.
98. Szalony JA, Haas NF, Salyers AK, et al. Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A. Circulation 1995;91:411-6.
99. Azrin MA, Ling FS, Chen Q, et al. Preparation, characterization, and evaluation of a monoclonal antibody against the rabbit platelet glycoprotein IIb/IIIa in an experimental angioplasty model. Circ Res 1994;75:268-77.
100. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
101. Coller BS, Scudder LE, Beer J, et al. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann N Y Acad Sci 1991; 614:193-213.
102. Choi ET, Engel L, Callow AD, et al. Inhibition of neointimal hyperplasia by blocking alpha V beta 3 integrin with a small peptide antagonist Gpen-GRGDSPCA. J Vasc Surg 1994;19:125-34.
103. Hill-West JL, Chowdhury SM, Slepian MJ, Hubbell JA. Inhibition of thrombosis and intimal thickening by in situ photopolymerization of thin hydrogel barriers. Proc Natl Acad Sci USA 1994;91:5967-71.
104. Lundgren CH, Sawa H, Fujii S. Inhibition of neointimal hyperplasia after balloon injury by local delivery of a cyclic arginine-glycine-aspartic acid peptide targeting vitronectin receptor [abstract]. J Am Coll Cardiol 1995; 25:83A.
105. Gralnick HR, Williams S, McKeown L, et al. A monomeric von-Willebrand factor fragment, Leu-504-Ser-728, inhibits von-Willebrand factor interaction with glycoprotein Ib-IX. Proc Natl Acad Sci USA 1992;89:7880-4.
106. Badimon J, Fuster V, Badimon L. Inhibition of glycoprotein Ib binding domain inhibits platelet deposition on damaged vessel wall [abstract]. Circulation 1991;84 Suppl II(Pt 4):II-264A.
107. Zahger D, Fishbein MC, Garfinkel LI, et al. VCL, an antagonist of the platelet GP1b receptor, markedly inhibits platelet adhesion and intimal thickening after balloon injury in the rat. Circulation 1995;92:1269-73.